In a filing, Vertex Pharmaceuticals, Inc revealed its Director LR 2019 Benefit Trust acquired Company’s shares for reported $76021.0 on May 21 ’25. In the deal valued at $447.18 per share,170 shares were bought.
Then, SR 2019 Benefit Trust bought 170 shares, generating $76,021 in total proceeds.
Before that, ALTSHULER DAVID sold 52 shares. Vertex Pharmaceuticals, Inc shares valued at $22,084 were divested by the EVP, Chief Scientific Officer at a price of $424.69 per share. As a result of the transaction, ALTSHULER DAVID now holds 23,281 shares, worth roughly $10.5 million.
Wolfe Research downgraded its Vertex Pharmaceuticals, Inc [VRTX] rating to a Peer perform from a an Outperform in a research note published recently. A number of analysts have revised their coverage, including Leerink Partners’s analysts, who decreased its forecast for the stock in early May from “an Outperform” to “a Market perform”. Canaccord Genuity revised its rating on February 12, 2025. It rated VRTX as “a Hold” which previously was an “a Sell”.
Price Performance Review of VRTX
On Monday, Vertex Pharmaceuticals, Inc [NASDAQ:VRTX] saw its stock fall -1.00% to $450.91. Over the last five days, the stock has gained 1.07%. Vertex Pharmaceuticals, Inc shares have risen nearly 11.97% since the year began. Nevertheless, the stocks have fallen -5.23% over the past one year. While a 52-week high of $519.88 was reached on 03/14/25, a 52-week low of $377.85 was recorded on 01/13/25.
Levels Of Support And Resistance For VRTX Stock
The 24-hour chart illustrates a support level at 447.34, which if violated will result in even more drops to 443.76. On the upside, there is a resistance level at 455.86. A further resistance level may holdings at 460.80.
